Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexlansoprazole for pediatric erosive esophagitis
2014-004507-73Phase 2Terminated
- Sponsor
- Takeda
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, double-blind trial of dexlansoprazole in erosive esophagitis (EE) and gastroesophageal reflux disease (GERD) (2 arms), sponsored by Takeda. Primary endpoint: Healing of erosive esophagitis by Week 12. Started Nov 2015; status: terminated.
02
Drugs
dexlansoprazole
03
Conditions
erosive esophagitis (EE)gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on 2014-004507-73.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004507-73.